Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

(2019) Sven Wind et al.   CLINICAL PHARMACOKINETICS

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

(2019) Oliver Distler et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

(2019) Kevin R. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis

(2018) Ulrike Schmid et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Gastrointestinal involvement in systemic sclerosis

(2018) Zsuzsanna H. McMahan et al.   CURRENT OPINION IN RHEUMATOLOGY

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

(2018) Bruno Crestani et al.   Lancet Respiratory Medicine

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

(2015) Lutz Wollin et al.   EUROPEAN RESPIRATORY JOURNAL

Safety and Effectiveness of Mycophenolate in Systemic Sclerosis. A Systematic Review

(2015) Mohammed A. Omair et al.   PLoS One

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

(2013) Frank van den Hoogen et al.   ANNALS OF THE RHEUMATIC DISEASES

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

(2013) Manuela Schmidinger   EJC SUPPLEMENTS

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

(2011) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Vascular Endothelial Growth Factor in Wound Healing

(2008) Philip Bao et al.   JOURNAL OF SURGICAL RESEARCH